Pharmacyte Biotech Inc. (PMCB) 0.1541 $PMCB
The "Tech" Behind Biotechnology Has Evolved; 2015 Marks New Milestones
ACCESSWIRE - Thu May 07, 10:01AM CDT
CORAL GABLES, FL / ACCESSWIRE / May 7, 2015 / The biotechnology industry has come a long way from where it was even 10 years ago. New findings, developments, and enacted regulations have given rise to programs only once dreamed of. Nearly half of America is behind the legalization of cannabis; many in favor of medical use and other novel therapies to treat the effects of cancer. Companies like Oxis International, Inc. (OTCQB: OXIS), PlasmaTech Biopharmaceuticals, Inc. (NASDAQ: PTBI), and PharmaCyte Biotech, Inc. (OTCQB: PMCB) have all begun the push for brining certain therapies to market.
PTBI: 8.29 (+0.31)
PharmaCyte Biotech's Melligen Cells Prove Safe in First Preclinical Test
GlobeNewswire - Wed May 06, 8:30AM CDT
PharmaCyte Biotech, Inc. (OTCQB
MCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, today announced that the Institute of Virology at the University of Veterinary Medicine Vienna, one of the partners in PharmaCyte Biotech's international Diabetes Consortium, has completed the first round of safety testing of the Melligen cells in mice.
Unprecedented Diabetes Research Collaboration to Lead to Expedited PharmaCyte Biotech Clinical Trials
PR Newswire - Tue Apr 28, 8:30AM CDT
Goldman Small Cap Research, a stock market research firm specializing in the small cap and microcap sectors, announced today that it has issued a new sponsored research article on PharmaCyte Biotech, Inc. (OTCQB - PMCB), a publicly traded, clinical stage biotechnology company focused on developing and preparing treatments for cancer and diabetes. To view the new, sponsored research article, previous reports, updates and articles, along with disclosures and disclaimers, or to download them in their entirety, please visit www.GoldmanResearch.com.
PharmaCyte Biotech Awaits Pivotal U.S. Study Results Expected to Lead to Human Clinical Trials
Marketwired - Thu Apr 23, 8:20AM CDT
PharmaCyte Biotech (OTCQB: PMCB) is not a big company by any means, but their lineup of treatments is certainly standing tall these days. The international biotech firm is already set to head into Phase 2b clinical trials in advanced inoperable pancreatic cancer later this year in Australia. PharmaCyte even made headlines in the diabetes industry two weeks ago after a study was published that stated its Melligen cell line could produce insulin in diabetic mice.
PharmaCyte Biotech: Smells Like A Pump And Dump
Weighing Machine - at Seeking Alpha - Wed Apr 22, 2:54PM CDT
PharmaCyte Biotech Moving Closer to Human Clinical Trials Around an Elite New Leadership Team
PR Newswire - Wed Apr 22, 8:30AM CDT
Goldman Small Cap Research, a stock market research firm specializing in the small cap and microcap sectors, announced today that it has issued a new sponsored research article on PharmaCyte Biotech, Inc. (OTCQB - PMCB), a publicly traded, clinical stage biotechnology company focused on developing and preparing treatments for cancer and diabetes. To view the sponsored research article, along with disclosures and disclaimers, or to download it and previous articles in their entirety, please visit www.GoldmanResearch.com.
Human Preclinical Study Significant Milestone; PharmaCyte Biotech Analyst Brief Issued by BrokerBank Securities, Inc.
PR Newswire - Wed Apr 22, 6:00AM CDT
PharmaCyte Biotech, Inc. (OTCMRKTS: PMCB) is a Biotechnology company that was founded in 1996 in Maryland. The company utilizes a cellulose-based live cell encapsulation technology (Cell in-a-Box) to develop treatments for pancreatic cancer, breast cancer, brain cancer and diabetes. The company operates independently and through wholly-owned subsidiaries. PharmaCyte Biotech has three operations. The first of these includes the cellulose-based live cell encapsulation technology. The second pertains to the work of its subsidiary, Medical Marijuana Sciences, Inc. (MMS). MMS focuses on ways to exploit the benefits of the live cell encapsulation technology in optimizing the anticancer effectiveness of constituents of Cannabis (cannabinoids) against cancers. The third segment consists of the company's nutraceutical formulations and their associated product names and information technology. This segment has a focus on selling its nutraceutical formulations and associated information technology.
Reviews Of 15 Marijuana Stocks Before The Marijuana Investor Summit - Part X
Anthony Cataldo - at Seeking Alpha - Tue Apr 21, 6:30AM CDT
XXII: 1.08 (+0.01), VPCO: 0.56 (+0.01)
PharmaCyte Biotech Finalizes International Diabetes Consortium to Cure Diabetes
GlobeNewswire - Mon Apr 20, 8:30AM CDT
PharmaCyte Biotech, Inc. (OTCQBMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, today announced that the world class team of scientists, physicians and academics that make up its international Diabetes Consortium is now complete with the addition of the final two members, Dr. Thomas Stratmann and Dr. Axel Kornerup Hansen.
PharmaCyte Biotech Appoints Former Pfizer and Alchemia Executive to Board of Directors
GlobeNewswire - Tue Apr 14, 8:30AM CDT
PharmaCyte Biotech, Inc. (OTCQBMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, announced today that Thomas Liquard has joined its Board of Directors and will become Chairman of the Audit Committee. Mr. Liquard is a seasoned pharmaceutical industry executive whose past experiences include serving as Chief Executive of Alchemia Limited and as Senior Director, Portfolio Development Leader, Emerging Markets for the Established Products portfolio for Pfizer in New York.
Major Paper Shows How Melligen Cell Line Derived from Human Liver Cells Can Reverse Diabetes
ACCESSWIRE - Mon Apr 13, 7:02AM CDT
SILVER SPRING, MD / ACCESSWIRE / April 13, 2015 / Recently published paper in the scientific journal Molecular Therapy - Methods & Clinical Development puts the spotlight on novel research that has been done by a team at University of Technology Sydney (UTS) and the University of Sydney in Australia. The research team observed that a cell line called "Melligen" cells that was derived from human liver cells show real promise as a potential treatment for Type 1 diabetes because these cell are capable of regulating blood glucose (sugar) levels by producing insulin on demand. This observation, noted the authors, illustrates that Melligen cells can reverse the diabetic condition.
New Research Shows PharmaCyte Biotech's Melligen Cell Line Can Reverse Diabetes
GlobeNewswire - Fri Apr 10, 8:32AM CDT
PharmaCyte Biotech, Inc. (OTCQBMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, today announced that Prof. Ann Simpson (a member of PharmaCyte Biotech's international Diabetes Consortium) and her colleagues at the University of Technology Sydney and the University of Sydney in Australia have published a major research article titled "Reversal of diabetes following transplantation of an insulin-secreting human liver cell line: Melligen cells" in the journal Molecular Therapy - Methods & Clinical Development.
PharmaCyte Biotech's Novel Approach to Brain Cancer
PR Newswire - Thu Apr 09, 7:45AM CDT
Goldman Small Cap Research, a stock market research firm specializing in the small cap and microcap sectors, announced today that it has issued a new article on PharmaCyte Biotech, Inc. (OTCQB - PMCB), a publicly traded, clinical stage biotechnology company focused on developing and preparing treatments for cancer and diabetes. To view the sponsored research article, along with disclosures and disclaimers, or to download it in its entirety, please visit www.GoldmanResearch.com.
Flurry of Biotech Mergers and Acquisitions Bodes Well for PharmaCyte Biotech
PR Newswire - Wed Apr 01, 7:45AM CDT
Goldman Small Cap Research, a stock market research firm specializing on the small cap and microcap sectors, announced today that it has issued a new article on PharmaCyte Biotech, Inc. (OTCQB - PMCB), a publicly traded clinical stage biotechnology company focused on developing and preparing treatments for cancer and diabetes. To view the sponsored research article, along with disclosures and disclaimers, or to download it in its entirety, please visit www.GoldmanResearch.com.
PharmaCyte Biotech: Trials Set To Start In Q3, I'm Still Skeptical
Jack Banser - at Seeking Alpha - Mon Mar 30, 1:55PM CDT
PharmaCyte Biotech on Track to Commence Clinical Trials
GlobeNewswire - Fri Mar 27, 8:00AM CDT
PharmaCyte Biotech, Inc. (OTCQBMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, today announced that the genetically modified cells that are required for its three planned clinical trials have been fully tested and are in the process of being propagated to produce all of the cells necessary for the clinical trials.
Goldman Small Cap Research Issues Research Report on PharmaCyte Biotech, Inc.
PR Newswire - Thu Mar 26, 7:40AM CDT
Goldman Small Cap Research, a stock market research firm specializing on the small cap and microcap sectors, announced today that it has issued a research report on PharmaCyte Biotech, Inc. (OTCQB - PMCB), a publicly traded clinical stage biotechnology company focused on developing and preparing treatments for cancer and diabetes. The report carries a rating and a price target. To view the sponsored research report, along with disclosures and disclaimers, or to download it in its entirety, please visit www.GoldmanResearch.com.
Penny Stocks Reports for EnzymeBioSystems, Sigma Labs, NanoTech Entertainment, Anavex Life Sciences, BIRCHCLIFF, and Pharmacyte Biotech
PR Newswire - Fri Mar 20, 7:45AM CDT
Pennystocksinsiders.com (PSI) released FREE insider trading reports for US market investors to track the following active stocks and penny stocks: EnzymeBioSystems (OTCBB:ENZB), Sigma Labs (OTCMKTS:SGLB), NanoTech Entertainment (OTCMKTS:NTEK), Anavex Life Sciences (OTCMKTS:AVXL), BIRCHCLIFF (OTCMKTS:BIREF), and Pharmacyte Biotech (OTCMKTSMCB).
PharmaCyte Biotech's "Factory" of Live Cells Takes Direct Aim at Cancer Tumors Armed With FDA Orphan Drug Status
Marketwired - Wed Mar 18, 8:02AM CDT
PharmaCyte Biotech (OTCQB: PMCB) is aiming directly at the problem patients with advanced pancreatic cancer face, an inoperable tumor! PharmaCyte owns the exclusive worldwide rights to develop treatments for all types of solid cancerous tumors using its signature Cell-in-a-Box technology combined with low doses of the chemotherapy drug ifosfamide. It is this treatment (Cell-in-a-Box/ifosfamide) that was just awarded with the U.S. Food and Drug Administration's (FDA) Orphan Drug designation. Armed with the FDA's Orphan Drug designation, PharmaCyte can now take direct aim at becoming the treatment of choice for advanced pancreatic cancer.
PharmaCyte Biotech Provides Update on Corporate Developments and Progress With Cancer and Diabetes Programs
GlobeNewswire - Mon Mar 16, 7:30AM CDT
PharmaCyte Biotech, Inc. (OTCQBMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, today provided shareholders with an update on developments on progress in its cancer and diabetes programs and at the corporate level.
The "Tech" Behind Biotechnology Has Evolved; 2015 Marks New Milestones
ACCESSWIRE - Thu May 07, 10:01AM CDT
CORAL GABLES, FL / ACCESSWIRE / May 7, 2015 / The biotechnology industry has come a long way from where it was even 10 years ago. New findings, developments, and enacted regulations have given rise to programs only once dreamed of. Nearly half of America is behind the legalization of cannabis; many in favor of medical use and other novel therapies to treat the effects of cancer. Companies like Oxis International, Inc. (OTCQB: OXIS), PlasmaTech Biopharmaceuticals, Inc. (NASDAQ: PTBI), and PharmaCyte Biotech, Inc. (OTCQB: PMCB) have all begun the push for brining certain therapies to market.
PTBI: 8.29 (+0.31)
PharmaCyte Biotech's Melligen Cells Prove Safe in First Preclinical Test
GlobeNewswire - Wed May 06, 8:30AM CDT
PharmaCyte Biotech, Inc. (OTCQB
MCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, today announced that the Institute of Virology at the University of Veterinary Medicine Vienna, one of the partners in PharmaCyte Biotech's international Diabetes Consortium, has completed the first round of safety testing of the Melligen cells in mice. Unprecedented Diabetes Research Collaboration to Lead to Expedited PharmaCyte Biotech Clinical Trials
PR Newswire - Tue Apr 28, 8:30AM CDT
Goldman Small Cap Research, a stock market research firm specializing in the small cap and microcap sectors, announced today that it has issued a new sponsored research article on PharmaCyte Biotech, Inc. (OTCQB - PMCB), a publicly traded, clinical stage biotechnology company focused on developing and preparing treatments for cancer and diabetes. To view the new, sponsored research article, previous reports, updates and articles, along with disclosures and disclaimers, or to download them in their entirety, please visit www.GoldmanResearch.com.
PharmaCyte Biotech Awaits Pivotal U.S. Study Results Expected to Lead to Human Clinical Trials
Marketwired - Thu Apr 23, 8:20AM CDT
PharmaCyte Biotech (OTCQB: PMCB) is not a big company by any means, but their lineup of treatments is certainly standing tall these days. The international biotech firm is already set to head into Phase 2b clinical trials in advanced inoperable pancreatic cancer later this year in Australia. PharmaCyte even made headlines in the diabetes industry two weeks ago after a study was published that stated its Melligen cell line could produce insulin in diabetic mice.
PharmaCyte Biotech: Smells Like A Pump And Dump
Weighing Machine - at Seeking Alpha - Wed Apr 22, 2:54PM CDT
PharmaCyte Biotech Moving Closer to Human Clinical Trials Around an Elite New Leadership Team
PR Newswire - Wed Apr 22, 8:30AM CDT
Goldman Small Cap Research, a stock market research firm specializing in the small cap and microcap sectors, announced today that it has issued a new sponsored research article on PharmaCyte Biotech, Inc. (OTCQB - PMCB), a publicly traded, clinical stage biotechnology company focused on developing and preparing treatments for cancer and diabetes. To view the sponsored research article, along with disclosures and disclaimers, or to download it and previous articles in their entirety, please visit www.GoldmanResearch.com.
Human Preclinical Study Significant Milestone; PharmaCyte Biotech Analyst Brief Issued by BrokerBank Securities, Inc.
PR Newswire - Wed Apr 22, 6:00AM CDT
PharmaCyte Biotech, Inc. (OTCMRKTS: PMCB) is a Biotechnology company that was founded in 1996 in Maryland. The company utilizes a cellulose-based live cell encapsulation technology (Cell in-a-Box) to develop treatments for pancreatic cancer, breast cancer, brain cancer and diabetes. The company operates independently and through wholly-owned subsidiaries. PharmaCyte Biotech has three operations. The first of these includes the cellulose-based live cell encapsulation technology. The second pertains to the work of its subsidiary, Medical Marijuana Sciences, Inc. (MMS). MMS focuses on ways to exploit the benefits of the live cell encapsulation technology in optimizing the anticancer effectiveness of constituents of Cannabis (cannabinoids) against cancers. The third segment consists of the company's nutraceutical formulations and their associated product names and information technology. This segment has a focus on selling its nutraceutical formulations and associated information technology.
Reviews Of 15 Marijuana Stocks Before The Marijuana Investor Summit - Part X
Anthony Cataldo - at Seeking Alpha - Tue Apr 21, 6:30AM CDT
XXII: 1.08 (+0.01), VPCO: 0.56 (+0.01)
PharmaCyte Biotech Finalizes International Diabetes Consortium to Cure Diabetes
GlobeNewswire - Mon Apr 20, 8:30AM CDT
PharmaCyte Biotech, Inc. (OTCQB
MCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, today announced that the world class team of scientists, physicians and academics that make up its international Diabetes Consortium is now complete with the addition of the final two members, Dr. Thomas Stratmann and Dr. Axel Kornerup Hansen. PharmaCyte Biotech Appoints Former Pfizer and Alchemia Executive to Board of Directors
GlobeNewswire - Tue Apr 14, 8:30AM CDT
PharmaCyte Biotech, Inc. (OTCQB
MCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, announced today that Thomas Liquard has joined its Board of Directors and will become Chairman of the Audit Committee. Mr. Liquard is a seasoned pharmaceutical industry executive whose past experiences include serving as Chief Executive of Alchemia Limited and as Senior Director, Portfolio Development Leader, Emerging Markets for the Established Products portfolio for Pfizer in New York. Major Paper Shows How Melligen Cell Line Derived from Human Liver Cells Can Reverse Diabetes
ACCESSWIRE - Mon Apr 13, 7:02AM CDT
SILVER SPRING, MD / ACCESSWIRE / April 13, 2015 / Recently published paper in the scientific journal Molecular Therapy - Methods & Clinical Development puts the spotlight on novel research that has been done by a team at University of Technology Sydney (UTS) and the University of Sydney in Australia. The research team observed that a cell line called "Melligen" cells that was derived from human liver cells show real promise as a potential treatment for Type 1 diabetes because these cell are capable of regulating blood glucose (sugar) levels by producing insulin on demand. This observation, noted the authors, illustrates that Melligen cells can reverse the diabetic condition.
New Research Shows PharmaCyte Biotech's Melligen Cell Line Can Reverse Diabetes
GlobeNewswire - Fri Apr 10, 8:32AM CDT
PharmaCyte Biotech, Inc. (OTCQB
MCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, today announced that Prof. Ann Simpson (a member of PharmaCyte Biotech's international Diabetes Consortium) and her colleagues at the University of Technology Sydney and the University of Sydney in Australia have published a major research article titled "Reversal of diabetes following transplantation of an insulin-secreting human liver cell line: Melligen cells" in the journal Molecular Therapy - Methods & Clinical Development. PharmaCyte Biotech's Novel Approach to Brain Cancer
PR Newswire - Thu Apr 09, 7:45AM CDT
Goldman Small Cap Research, a stock market research firm specializing in the small cap and microcap sectors, announced today that it has issued a new article on PharmaCyte Biotech, Inc. (OTCQB - PMCB), a publicly traded, clinical stage biotechnology company focused on developing and preparing treatments for cancer and diabetes. To view the sponsored research article, along with disclosures and disclaimers, or to download it in its entirety, please visit www.GoldmanResearch.com.
Flurry of Biotech Mergers and Acquisitions Bodes Well for PharmaCyte Biotech
PR Newswire - Wed Apr 01, 7:45AM CDT
Goldman Small Cap Research, a stock market research firm specializing on the small cap and microcap sectors, announced today that it has issued a new article on PharmaCyte Biotech, Inc. (OTCQB - PMCB), a publicly traded clinical stage biotechnology company focused on developing and preparing treatments for cancer and diabetes. To view the sponsored research article, along with disclosures and disclaimers, or to download it in its entirety, please visit www.GoldmanResearch.com.
PharmaCyte Biotech: Trials Set To Start In Q3, I'm Still Skeptical
Jack Banser - at Seeking Alpha - Mon Mar 30, 1:55PM CDT
PharmaCyte Biotech on Track to Commence Clinical Trials
GlobeNewswire - Fri Mar 27, 8:00AM CDT
PharmaCyte Biotech, Inc. (OTCQB
MCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, today announced that the genetically modified cells that are required for its three planned clinical trials have been fully tested and are in the process of being propagated to produce all of the cells necessary for the clinical trials. Goldman Small Cap Research Issues Research Report on PharmaCyte Biotech, Inc.
PR Newswire - Thu Mar 26, 7:40AM CDT
Goldman Small Cap Research, a stock market research firm specializing on the small cap and microcap sectors, announced today that it has issued a research report on PharmaCyte Biotech, Inc. (OTCQB - PMCB), a publicly traded clinical stage biotechnology company focused on developing and preparing treatments for cancer and diabetes. The report carries a rating and a price target. To view the sponsored research report, along with disclosures and disclaimers, or to download it in its entirety, please visit www.GoldmanResearch.com.
Penny Stocks Reports for EnzymeBioSystems, Sigma Labs, NanoTech Entertainment, Anavex Life Sciences, BIRCHCLIFF, and Pharmacyte Biotech
PR Newswire - Fri Mar 20, 7:45AM CDT
Pennystocksinsiders.com (PSI) released FREE insider trading reports for US market investors to track the following active stocks and penny stocks: EnzymeBioSystems (OTCBB:ENZB), Sigma Labs (OTCMKTS:SGLB), NanoTech Entertainment (OTCMKTS:NTEK), Anavex Life Sciences (OTCMKTS:AVXL), BIRCHCLIFF (OTCMKTS:BIREF), and Pharmacyte Biotech (OTCMKTS
MCB). PharmaCyte Biotech's "Factory" of Live Cells Takes Direct Aim at Cancer Tumors Armed With FDA Orphan Drug Status
Marketwired - Wed Mar 18, 8:02AM CDT
PharmaCyte Biotech (OTCQB: PMCB) is aiming directly at the problem patients with advanced pancreatic cancer face, an inoperable tumor! PharmaCyte owns the exclusive worldwide rights to develop treatments for all types of solid cancerous tumors using its signature Cell-in-a-Box technology combined with low doses of the chemotherapy drug ifosfamide. It is this treatment (Cell-in-a-Box/ifosfamide) that was just awarded with the U.S. Food and Drug Administration's (FDA) Orphan Drug designation. Armed with the FDA's Orphan Drug designation, PharmaCyte can now take direct aim at becoming the treatment of choice for advanced pancreatic cancer.
PharmaCyte Biotech Provides Update on Corporate Developments and Progress With Cancer and Diabetes Programs
GlobeNewswire - Mon Mar 16, 7:30AM CDT
PharmaCyte Biotech, Inc. (OTCQB
MCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, today provided shareholders with an update on developments on progress in its cancer and diabetes programs and at the corporate level. 
